Improving health

As a pharmaceutical manufacturer, we have a responsibility to help improve the health of patients and communities worldwide. Thanks to our extensive production capacity, the antibiotics we produce support about 30% of all penicillin-based antibiotic treatments.

In 2018 and 2019, we continued to forward-integrate our business and become closer to the end users of our products. We secured multiple new product/market approvals for our finished dosage forms (FDFs).

We launched Project PNEC, designed to comply with the AMR Industry Alliance’s safe discharge targets. Already in 2019 we met the stringent PNEC targets for our largest portfolio range of SSP APIs, two years ahead of schedule.

We also expanded our efforts to support the health and well-being of the local communities where we operate.

The relevant 'priority topics’ for the Improving Health chapter are:

Improving Access

We can help improve quality of life, by making sure vital medicines are accessible to those who need them.

Antimicrobial Resistance (AMR)

We advocate for responsible antibiotics manufacturing and usage, starting with our own operations.

Our progress

171

new product/market registrations for FDFs during 2019-2019

‘Project Appropriate use in China’ AMR campaign launched in 70 hospitals

PNEC

Stringent PNEC targets met for our largest portfolio range of SSP APIs, 2 years ahead of schedule

3400

patients treated at Centrient’s free clinic in India

87%

of our FDF sustainable manufacturing has been assessed and found compliant with the PNEC targets

600

homes in India got clean drinking water supply

Access to medicines

Centrient Pharmaceuticals plays an important role in the reliable manufacturing of critical medicines and their delivery to patients. In 2018 and 2019, we continued to develop and expand our supply chains to ensure our pharmaceutical products reach patients around the globe.

Thanks to the wide regulatory coverage of our API business, we are able to sell our products in virtually any market worldwide. We also work hard to gain new product/market approvals for registrations of our FDFs: we secured 91 new approvals in 2018 and 80 in 2019.

An evolving healthcare landscape

2018 and 2019 were critical years in the pharmaceutical industry’s development with regard to sustainability, health and the environment. We took steps to further integrate sustainability-related criteria into our tender processes with the aim of increase supplier standards.

In 2012, Centrient developed the PureActives® brand, based on a revolutionary enzymatic production platform for antibiotics and statins. In 2019, the PureActives® brand was included in one of our customers’ product marketing campaign for the first time.

AMR and non-communicable disease

As a member of the AMR Industry Alliance, Centrient advocates for the responsible manufacturing and use of antibiotics through our Sustainable Antibiotics programme.

In 2018, the first Common Antibiotic Manufacturing Framework was established by the Alliance. Since then, the members have also adopted science-based liquid discharge targets (also known as Predicted No-Effect Concentrations, or PNEC) for antibiotics discharged from manufacturing operations. In 2019, Centrient was one of several companies to begin implementing the new standards across their supply chains.

Community impact

In 2018 and 2019, we introduced several new Corporate Social Responsibility (CSR) programmes, with a focus on India and Mexico. Many of our programmes centre on health and nutrition, while others have an educational focus. For example, Centrient provides financial support to four government schools across India. So far, our contribution helped improve their facilities, including buildings, classrooms and playgrounds. We also provided funding for two new teachers, as well as new uniforms and classroom equipment.